SEHK:1093Pharmaceuticals
Assessing CSPC Pharmaceutical Group (SEHK:1093) Valuation After Key PEComa Trial Success
CSPC Pharmaceutical Group (SEHK:1093) has flagged a key product milestone after its subsidiary reported that a Phase Ib/III trial of Sirolimus for Injection in advanced malignant PEComa met its primary efficacy endpoint in China.
See our latest analysis for CSPC Pharmaceutical Group.
The HB1901 trial news sits alongside a mixed share price picture, with CSPC Pharmaceutical Group’s HK$8.98 latest close coming after a 5.8% year to date share price return but an 8.5% 3 month share price decline,...